logo-loader
Kazia Therapeutics Ltd

Kazia Therapeutics developing unique drug to battle brain cancer

Kazia Therapeutics Limited (NASDAQ:KZIA)(ASX:KZA) CEO James Garner sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The Sydney, Australia based oncology-focused biotechnology company develops anti-cancer drugs; its pipeline includes two clinical-stage drug development candidates. Its lead candidate is GDC-0084, which has entered a phase II clinical trial in March 2018, with initial data expected in early calendar 2019.

Quick facts: Kazia Therapeutics Ltd

Price: $0.35

Market: ASX
Market Cap: $21.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kazia Therapeutics releases new safety data to assist in brain cancer treatments

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer James Garner speaks to Proactive Investors about new safety and tolerability data from the company's phase-IIa clinical trial of brain cancer treatment.    Garner said the superior results from the ongoing study of...

on 05/07/2019

2 min read